Management
Prof. Dr. Detlef Goelling, Director Development
Prof. Dr. Detlef Goelling has been the Director of the Development Department at ORGANOBALANCE since 2007. He is responsible in this capacity for process development and process optimisation. In the 10 years prior to commencing work at ORGANOBALANCE he was a group manager at DANISCO, where he was in charge of process development. He worked as a project manager at NOVARTIS. Detlef Goelling did his doctorate in the field of biotechnology and had a postdoctoral position at SCHERING AG. He has been an honorary professor at University of Applied Sciences Flensburg since 2007.
Dr. Caterina Holz, Director Clinical Research
Dr. Caterina Holz has been the Director of Research at ORGANOBALANCE since 2008. She brings experience from the biotechnology sector, pharmaceutical industry and food industry through her work as a laboratory supervisor with PSF biotech AG, Boehringer Ingelheim and C.A.S. S.p.A. Caterina Holz has a doctorate in biotechnology and has worked as a team leader at the TU Berlin and the Max Planck Institute for Molecular Genetics, where she conducted research in the fields of gene expression in yeast and analysis of genome function.
Dr. Klaus Pellengahr, Director Business Development
Dr. Klaus Pellengahr is leading the Business Development of ORGANOBALANCE since 2010. He holds a PhD in Molecular Biology and has been involved in numerous product developments based on microbial strains and enzymes. These included new applications in pharma, food, feed, biofuels and biocatalysis. Before starting at ORGANOBALANCE he worked as a project manager and Head of Molecular Biology at Direvo AG in Cologne and as Head of Business Development at c-LEcta GmbH in Leipzig.
Dr. Andreas Raab, Director Research
Dr. Andreas Raab has been project and group leader at ORGANOBALANCE since 2006. Since 2010 he has been a member of the management board. He is responsible for the division "metabolic engineering and white biotechnology". Andreas Raab is an engineer of biotechnology and did his doctorate in the field of "metabolic engineering" and strain development.
Bernd Wegener, DVM
Bernd Wegener. DVM, has extensive managerial experience from diverse areas of responsibility in the pharmaceutical industry and relevant associations. After holding positions at Boehringer Ingelheim KG, Degussa Pharmagruppe, Marion Merrell Dow GmbH and Henning Berlin GmbH, he was Founder and Chairman of the Board of the BRAHMS Group from 1994 to May 2010. Dr Wegener is also Chairman of the Board of the German Federal Association of the Pharmaceutical Industry (BPI) as well as being a member of the board of various associations and supervisory boards.